Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
91 patients receiving upfront immunochemotherapy to evaluate the differences in prognostic factors and mutational profiles.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Despite distinct clinical prognostic factors, mutational profiles were comparable between the two groups, even at clinical extremes. These findings underscore the challenges in predicting the duration of a WW approach.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
Follicular lymphoma (FL) exhibits considerable heterogeneity in clinical trajectories and molecular characteristics.
APA
Hesius EAM, Stewart JP, et al. (2025). Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors.. Leukemia & lymphoma, 66(13), 2504-2517. https://doi.org/10.1080/10428194.2025.2556177
MLA
Hesius EAM, et al.. "Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors.." Leukemia & lymphoma, vol. 66, no. 13, 2025, pp. 2504-2517.
PMID
41084378 ↗
Abstract 한글 요약
Follicular lymphoma (FL) exhibits considerable heterogeneity in clinical trajectories and molecular characteristics. This study assessed the association between clinical presentation, histopathological findings, and mutational profiles with the duration of a Watch-and-Wait (WW) strategy in a cohort of 124 FL patients managed with a WW approach at diagnosis. Median event-free survival (EFS) (time to treatment or death) was 29 months. Hemoglobin below <12 g/dL and a Ki-67 proliferation index ≥30% were associated with inferior EFS. Mutational analyses showed considerable variability between patients. mutations and high m7-FLIPI score correlated with inferior EFS, though present in only 4% and 15% of cases, respectively. WW patients were compared to 91 patients receiving upfront immunochemotherapy to evaluate the differences in prognostic factors and mutational profiles. Despite distinct clinical prognostic factors, mutational profiles were comparable between the two groups, even at clinical extremes. These findings underscore the challenges in predicting the duration of a WW approach.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.